Can doxepin prolong the QT interval, especially at doses above 25 mg, and what monitoring and precautions are recommended for at‑risk patients?

Doxepin and QTC Prolongation

Doxepin, as a tricyclic antidepressant, does prolong the QT interval in a dose-dependent manner, particularly at therapeutic doses above 75 mg, and requires baseline and follow-up ECG monitoring in patients with cardiac risk factors. 1

Evidence for QT Prolongation

The FDA label explicitly documents that doxepin causes cardiovascular effects including QT prolongation, with ECG changes being "clinically significant indicators of tricyclic antidepressant toxicity" 1. Research using signal-averaged electrocardiography demonstrated that doxepin at a mean dose of 169 mg daily significantly prolonged the corrected QT interval from 417 to 439 milliseconds (p < 0.03) after 6 weeks of treatment 2. This represents clinically meaningful prolongation even at standard therapeutic doses.

Tricyclic antidepressants as a class carry substantial cardiac risk. A large Danish registry study found tricyclic antidepressants increased the risk of out-of-hospital cardiac arrest with an odds ratio of 1.69, higher than SSRIs (OR 1.21) 3. The mechanism involves blockade of cardiac potassium channels (IKr), which delays ventricular repolarization 2.

Dose-Dependent Risk

The QT prolongation risk increases with dose. The FDA label notes that QRS duration (a marker of cardiac conduction) correlates directly with serum doxepin concentrations (r = 0.78, p < 0.0001) 2. While the FDA label discusses doses up to 300 mg daily for severe illness 1, the cardiac risk escalates substantially at higher doses, particularly in overdose situations where "changes in QRS axis or width are clinically significant indicators of tricyclic antidepressant toxicity" 1.

Monitoring Recommendations

For patients prescribed doxepin, obtain:

• Baseline ECG before initiating therapy, particularly if any cardiac risk factors are present
• Follow-up ECG at 2-6 months after starting treatment, especially when doses exceed 75-100 mg daily
• Additional ECG monitoring if dose is increased above 150 mg daily or if symptoms develop

The FDA label specifically warns about cardiovascular effects and notes that "deaths have been reported involving overdoses of doxepin" with cardiac dysrhythmias as critical manifestations 1.

High-Risk Populations Requiring Enhanced Monitoring

Avoid doxepin or use with extreme caution and close ECG monitoring in patients with:

• Pre-existing QT prolongation (baseline QTc >450 ms in men, >470 ms in women)
• Structural heart disease (ischemic heart disease, heart failure, cardiomyopathies) 3
• Congenital long QT syndrome 3
• Electrolyte abnormalities (hypokalemia, hypomagnesemia) 4
• Age >65 years 4
• Bradycardia
• Concurrent use of other QT-prolonging medications 3
• Hepatic or renal impairment affecting drug clearance 1

Drug Interactions

Doxepin is metabolized by CYP2D6, and concomitant use of CYP2D6 inhibitors (quinidine, fluoxetine, paroxetine, cimetidine) can increase plasma concentrations 8-fold, substantially increasing cardiac risk 1. The FDA label warns that individuals on stable TCA doses "may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy" 1.

Clinical Thresholds for Concern

While no absolute threshold guarantees safety, general risk stratification suggests:

• QTc >500 ms: High risk for Torsades de Pointes—discontinue doxepin 5
• QTc 450-500 ms: Moderate risk—reduce dose, correct electrolytes, increase monitoring frequency
• QTc increase ≥60 ms from baseline: Significant prolongation—reassess need for medication 1

Practical Management Algorithm

1. Before prescribing: Obtain ECG if patient has any cardiac risk factors, is >65 years old, or will receive doses >75 mg daily
2. During treatment: Recheck ECG at 2-6 months, especially if dose exceeds 100 mg daily
3. If QTc prolongs: Correct electrolytes (maintain K+ >4.0 mEq/L, Mg2+ >2.0 mg/dL), review all medications for interactions, reduce doxepin dose or switch to alternative with lower cardiac risk
4. In overdose: Immediate ECG, continuous cardiac monitoring for minimum 6 hours, sodium bicarbonate if QRS >100 ms 1

Common Pitfalls

• Standard 12-lead ECG may miss subtle changes: The research study found that signal-averaged ECG detected QT prolongation that standard 12-lead ECG missed 2, but standard ECG remains the practical clinical tool
• Heart rate correction matters: Use Bazett's formula (QTc = QT/√RR) but recognize it overcorrects at high heart rates—doxepin also increases heart rate (69 to 81 bpm in studies) 2, which can mask QT prolongation
• Elderly patients are particularly vulnerable: The FDA label emphasizes careful dose adjustment in geriatric patients who should "generally be started on low doses" 1

The evidence clearly establishes doxepin as a QT-prolonging medication requiring cardiac monitoring, particularly at doses above 75-100 mg daily and in patients with additional risk factors.